- Home
- PRTC vs TACO Comparison
PRTC vs TACO Comparison
Compare PRTC & TACO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- TACO
- Stock Information
- Founded
- PRTC 2015
- TACO 2024
- Country
- PRTC United States
- TACO United States
- Employees
- PRTC N/A
- TACO N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- TACO Blank Checks
- Sector
- PRTC Health Care
- TACO Finance
- Exchange
- PRTC Nasdaq
- TACO Nasdaq
- Market Cap
- PRTC 413.5M
- TACO 389.8M
- IPO Year
- PRTC N/A
- TACO 2025
- Fundamental
- Price
- PRTC $16.75
- TACO $10.25
- Analyst Decision
- PRTC Buy
- TACO
- Analyst Count
- PRTC 1
- TACO 0
- Target Price
- PRTC $45.00
- TACO N/A
- AVG Volume (30 Days)
- PRTC 5.6K
- TACO 8.3K
- Earning Date
- PRTC 08-28-2025
- TACO 01-01-0001
- Dividend Yield
- PRTC N/A
- TACO N/A
- EPS Growth
- PRTC N/A
- TACO N/A
- EPS
- PRTC 0.20
- TACO N/A
- Revenue
- PRTC $6,391,000.00
- TACO N/A
- Revenue This Year
- PRTC N/A
- TACO N/A
- Revenue Next Year
- PRTC N/A
- TACO N/A
- P/E Ratio
- PRTC $7.61
- TACO N/A
- Revenue Growth
- PRTC 1265.60
- TACO N/A
- 52 Week Low
- PRTC $13.30
- TACO $10.10
- 52 Week High
- PRTC $24.99
- TACO $11.26
- Technical
- Relative Strength Index (RSI)
- PRTC 43.45
- TACO N/A
- Support Level
- PRTC $15.78
- TACO N/A
- Resistance Level
- PRTC $16.50
- TACO N/A
- Average True Range (ATR)
- PRTC 0.57
- TACO 0.00
- MACD
- PRTC -0.18
- TACO 0.00
- Stochastic Oscillator
- PRTC 25.17
- TACO 0.00
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About TACO Berto Acquisition Corp. Ordinary Shares
Berto Acquisition Corp is a blank check company.